Sleep Apnea – Pipeline Review, H2 2012

Date: July 31, 2012
Pages: 67
Price:
US$ 500.00 US$ 450.00
Offer valid until December 31, 2014!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: S547F9C6CA9EN
Leaflet:

Download PDF Leaflet

Sleep Apnea - Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Sleep Apnea - Pipeline Review, H2 2012', provides an overview of the Sleep Apnea therapeutic pipeline. This report provides information on the therapeutic development for Sleep Apnea, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Sleep Apnea. 'Sleep Apnea - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • A snapshot of the global therapeutic scenario for Sleep Apnea.
  • A review of the Sleep Apnea products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Sleep Apnea pipeline on the basis of route of administration and molecule type.
  • Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • Identify and understand important and diverse types of therapeutics under development for Sleep Apnea.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Sleep Apnea pipeline depth and focus of Sleep Apnea therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Sleep Apnea Therapeutic Products under Development, Key Players in Sleep Apnea Therapeutics, Sleep Apnea Pipeline Overview, Sleep Apnea Pipeline, Sleep Apnea Pipeline Assessment
Introduction
Global Markets Direct Report Coverage
Sleep Apnea Overview
Therapeutics Development
An Overview of Pipeline Products for Sleep Apnea
Sleep Apnea Therapeutics under Development by Companies
Sleep Apnea Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Sleep Apnea Therapeutics – Products under Development by Companies
Sleep Apnea Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Sleep Apnea Therapeutics Development
Merck & Co., Inc.
Novo Nordisk A/S
VIVUS, Inc.
Cortex Pharmaceuticals, Inc.
BIOPROJET SCR
Sleep Apnea – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
CX1739 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
MK-4305 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Qnexa - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Victoza - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
MK-7288 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Xenical - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Buspirone - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Caffeine - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Budesonide + Montelukast - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Pitolisant - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Caffeine - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Propofol Sedation - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Desogestrel - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Baclofen - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Zopiclone - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Sleep Apnea Therapeutics – Drug Profile Updates
Sleep Apnea Therapeutics – Discontinued Products
Sleep Apnea Therapeutics - Dormant Products
Sleep Apnea – Product Development Milestones
Featured News & Press Releases
Jun 08, 2012: Mylan Settles Provigil Litigation With Teva
Apr 30, 2012: Teva Settles Nuvigil Litigation With Mylan
Apr 18, 2012: Teva To Present New Data On NUVIGIL At 2012 American Academy Of Neurology Annual Meeting
Apr 05, 2012: Mylan Sues FDA Seeking Ruling That Teva Holds No Exclusivity For Generic Version Of Provigil
Jan 09, 2012: VIVUS Provides Update On Regulatory Status Of Qnexa
Nov 25, 2011: Alfresa Holdings And Mitsubishi Tanabe Pharma Announce Approval Of Additional Indication For Modiodal Tablets
Nov 03, 2011: FDA Accepts New Drug Application Filing For Qnexa
Apr 26, 2011: Cortex Receives US Patent For Lead AMPAKINE Molecule CX1739
Feb 02, 2011: Cortex’s Ampakine CX1739 Improves Respiratory Parameters In Obstructive Sleep Apnea Patients
Jan 25, 2011: Cephalon Announces Positive Topline Results From Phase IV Study Of NUVIGIL In Shift Work Disorder
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products Under Development for Sleep Apnea, H2 2012
Products under Development for Sleep Apnea – Comparative Analysis, H2 2012
Number of Products under Development by Companies, H2 2012
Number of Products under Investigation by Universities/Institutes, H2 2012
Comparative Analysis by Late Stage Development, H2 2012
Comparative Analysis by Mid Clinical Stage Development, H2 2012
Comparative Analysis by Early Clinical Stage Development, H2 2012
Products under Development by Companies, H2 2012
Products under Investigation by Universities/Institutes, H2 2012
Merck & Co., Inc., H2 2012
Novo Nordisk A/S, H2 2012
VIVUS, Inc., H2 2012
Cortex Pharmaceuticals, Inc., H2 2012
BIOPROJET SCR, H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Combination Products, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Stage and Molecule Type, H2 2012
Sleep Apnea Therapeutics – Drug Profile Updates
Sleep Apnea Therapeutics – Discontinued Products
Sleep Apnea Therapeutics – Dormant Products

LIST OF FIGURES

Number of Products under Development for Sleep Apnea, H2 2012
Products under Development for Sleep Apnea – Comparative Analysis, H2 2012
Products under Development by Companies, H2 2012
Products under Investigation by Universities/Institutes, H2 2012
Late Stage Products, H2 2012
Mid Clinical Stage Products, H2 2012
Early Clinical Stage Products, H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Combination Products, H2 2012
Assessment by Route of Administration, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Molecule Type, H2 2012
Assessment by Stage and Molecule Type, H2 2012
Sleep Apnea - Pipeline Review, Q4 2010 US$ 450.00 Nov, 2010 · 50 pages
Sleep Apnea - Pipeline Review, Q1 2011 US$ 450.00 Jan, 2011 · 32 pages
Sleep Apnea - Pipeline Review, Q3 2011 US$ 450.00 Jul, 2011 · 65 pages
Sleep Disorders - Pipeline Review, Q3 2011 US$ 450.00 Jul, 2011 · 136 pages

Ask Your Question

Sleep Apnea – Pipeline Review, H2 2012
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: